Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of the
investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in
patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators
intend to study the safety and tolerability of the study treatment, response to treatment,
time to disease progression, and overall survival.